Study of a new drug for relapsed B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called STR-P004 for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if the drug is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (ALL) that has either come back (relapsed) or has not responded to initial treatment.
- A recent bone marrow or blood test shows your leukemia cells are CD19-positive.
- Your bone marrow must show a certain percentage of leukemia cells (at least 5% blasts).
- You have adequate organ function, including acceptable blood counts, liver and kidney function, and heart health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
This study tests an experimental drug called STR-P005 for people with diseases that affect B cells, such as certain autoimmune or blood disorders. The goal is to see if the drug is safe and if it helps reduce your disease symptoms.
This study tests a new treatment (STR-P005) for autoimmune diseases. It aims to selectively target and deplete B cells that carry a specific marker, CD19, which may help reduce disease activity.
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.